Computer algorithms could help track and diagnose periodontal disease

Aldesleukin is under clinical development by Iovance Biotherapeutics and currently in Phase II for Graft Versus Host Disease (GVHD).

The investigational Bruton’s tyrosine kinase (BTK) inhibitor rilzabrutinib was associated with numerical decreases in loss of asthma control events for patients with poorly controlled asthma,

Updated population-based data showed that while lung cancer incidence rates are continuing to decline in the U.S., the higher rates previously observed in women versus